Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Wir haben kürzlich eine Liste mit den 11 am meisten unterbewerteten Pharma-Aktien erstellt, an denen man investieren kann. Grifols, S.A. (NASDAQ:GRFS) gehört zu den am meisten unterbewerteten Aktien.

TheFly berichtete am 12. Mai, dass Deutsche Bank das Kursziel von GRFS von €11 auf €10 reduzierte und gleichzeitig eine Hold-Bewertung bestätigte.

Früher am 7. Mai berichtete Grifols, S.A. (NASDAQ:GRFS) über seine Ergebnisse für das erste Quartal 2026. Das Unternehmen erzielte einen Gesamtumsatz von €1,7 Milliarden, was einem Zuwachs von 3,3% auf konstantem Wege gegenüber dem Vorjahr entspricht. Wachstum wurde hauptsächlich durch seine Biopharma-Sparte getrieben, die sich um 6,8% im konstanten Wege verbesserte, unterstützt durch starke Nachfrage nach Immunoglobulin-Produkten. Die Leistung wurde weiter gefördert durch den Rollout von Biotest's nächster Generation IVIG Yimmugo in den USA und das fortbestehende Momentum von Gamunex in wichtigen US-amerikanischen und europäischen Märkten. Diese Gewinne wurden teilweise durch schwächere Preise für Albumin in China und härtere Vergleichszeiten bei Alpha-1 und Spezialproteinen ausgeglichen.

Die Adjusted EBITDA des Unternehmens stieg auf €381 Millionen, was einem Zuwachs von 0,8% im konstanten Wege entspricht, mit einer stabilen Margen von 22,4%. Der Nettoerlös erreichte €73 Millionen, was einem Zuwachs von 21,9% gegenüber dem Vorjahr entspricht. Der Free Cash Flow vor M&A verbesserte sich auf negative €8 Millionen, während die Verschuldung bei 4,3x und die Liquidität bei €1,573 Milliarden lag, unterstützt durch kürzlich durchgeführte Refinanzierungsmaßnahmen, die Laufzeiten verlängerten und finanzielle Flexibilität stärkten.

Grifols, S.A. (NASDAQ:GRFS) ist ein globaler Gesundheitsdienstleister, der sich auf plasmabasierte Medikamente spezialisiert hat. Gegründet in Barcelona im Jahr 1909, bietet es biopharmazeutische Produkte und medizinische Dienstleistungen in über 110 Ländern an.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Markt für Kernicterus wächst aufgrund steigender Fälle von Neugeborenen-Jaundice, insbesondere bei Frühgeborenen. Haupttreiber sind Fortschritte in der Neugeborenen-Screening-Protokolle und die Entwicklung nicht-invasiver Diagnosewerkzeuge wie Transkutane Bilirubinometer. Phototherapie-Innovationen, einschließlich LED- und IoT-fähiger Systeme, verbessern Behandlungs-Effizienz und Patienten-Monitoring.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Intravenöse (IV)-Flüssigkeitsmarkt wird als ein wachsender Markt angesehen, der von verschiedenen Faktoren beeinflusst wird. Die Marktdynamik umfasst Treiber, Einschränkungen und Chancen, die für die Unternehmen im Markt relevant sind. Der Bericht bietet eine detaillierte Analyse des globalen IV-Flüssigkeitsmarktes, einschließlich der Segmentierung nach Material, Anwendung und Industriezweig. Die Studie enthält auch Informationen über die wichtigsten Akteure auf dem Markt, ihre Strategien und Produkte. Der Bericht ist ein wertvolles Werkzeug für Unternehmen, Investoren und Entscheidungsträger, um sich über den aktuellen Stand des Marktes zu informieren und zukünftige Trends und Entwicklungen vorherzusagen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Mithilfe der einfachen, visuellen Werkzeuge von Simply Wall St können Sie bessere Investitionsentscheidungen treffen. Warum ist Grifols-Aktien auf den Radar von Investoren geraten? Grifols (BME:GRF) hat frische Aufmerksamkeit erlangt nach einer Periode, in der die Renditen über verschiedene Zeiträume hinweg divergiert sind, mit Gewinnen im vergangenen Jahr gegenüber schwachen Bewegungen im Monat und den letzten 3 Monaten. Bei einem Schlusskurs von €8,94 spiegelt sich kürzlich ein kurzfristiger Druck wider. Gleichzeitig halten die langfristigen Zahlen und das aktuelle Earnings-Profil, einschließlich eines Umsatzes von €7.438,0 Mio. und einer Nettoertrags von €415,0 Mio., den Unternehmen im Fokus für Investoren, die Risiken und mögliche Renditen bewerten.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investing.com -- Die Aktien von Grifols fielen um 0,8% nachdem der spanische Hersteller von Plasma-Produkten im ersten Quartal Umsätze von €1,7 Milliarden meldete, ein Anstieg von 3,3% auf konstantem Wege, aber leicht unter dem Konsens von €1,72 Milliarden, da die Preisdynamik in China und eine schwierige Vergleichsbasis bei Spezialproteinen den Top-Linienwachstum beeinträchtigten.

Der Nettogewinn stieg um 21,9% im Vergleich zum Vorjahr auf €73 Millionen, während die angepasste EBITDA €381 Millionen erreichte, ein Anstieg von 0,8% auf konstantem Wege, mit stabilen Margen bei 22,4%.

Die Biopharma-Division blieb der Hauptwachstumsmotor, mit Umsätzen um 6,8% auf konstantem Wege.

Die Immunoglobulin-Franchise war die Hervorhebenswürdige Leistung, wobei sie um 15,3% auf konstantem Wege stieg, unterstützt durch nachhaltigen Bedarf an Gamunex in den USA und Kern-Europäischen Märkten sowie der US-Launch von Biotests nächster Generation IVIG-Produkt Yimmugo.

Albumin-Umsätze sanken um 6,1% auf konstantem Wege, reflektierend die anhaltende Regierungsförderung in China.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

If you are wondering whether Grifols at around €8.95 is a bargain or a value trap, you are not alone. The stock has been volatile, with a 4.5% decline over the past week, a 2.5% gain over the last month, a 20.1% decline year to date, a 6.5% return over the last year, and a 59.4% decline over five years. These swings have kept Grifols in the spotlight, as investors reassess both its long term prospects and the risks that might be priced into the shares. Recent coverage has focused on how sentiment is shifting after such a sharp multiyear pullback, and what that might mean for anyone considering the stock now. Against that backdrop, Grifols currently holds a valuation score of 4 out of 6. This reflects where it screens as undervalued on several checks, and the rest of this article will unpack how different valuation methods line up on the stock and point you to an even more complete way to think about value at the end.

Find out why Grifols's 6.5% return over the last year is lagging behind its peers.

Approach 1: Grifols Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business might be worth by projecting its future cash flows and discounting them back to today to reflect risk and the time value of money.

For Grifols, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows available to shareholders. The latest twelve month free cash flow is about €657.2 million. Analyst projections and extrapolations used by Simply Wall St imply free cash flow of €1,618.0 million by 2030, with interim annual estimates between 2026 and 2035 discounted back to today and summed.

On this basis, the DCF model arrives at an estimated intrinsic value of about €24.06 per share. Compared with the recent share price around €8.95, this implies the stock screens as roughly 62.8% undervalued in this framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Grifols is undervalued by 62.8%. Track this in your watchlist or portfolio, or discover 235 more high quality undervalued stocks.GRF Discounted Cash Flow as at Apr 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Grifols.

Approach 2: Grifols Price vs Earnings

For profitable companies, the P/E ratio is a useful gauge because it links what you pay for the stock to the earnings the business is currently generating. Investors usually accept a higher P/E when they expect stronger growth or see lower risk, and look for a lower P/E when growth expectations are more modest or risks feel higher.

Story Continues

Grifols currently trades on a P/E of 15.15x. This sits below the Biotechs industry average P/E of 26.91x and the peer group average of 32.27x. On the surface, that suggests the market is applying a discount to Grifols compared with its sector and closer peers.

Simply Wall St also uses a proprietary “Fair Ratio” to estimate what a more tailored P/E might look like for Grifols, based on factors such as earnings growth, profit margins, industry, market cap and specific risks. This Fair Ratio is 31.37x, which is designed to be more company specific than a simple comparison with broad industry or peer averages.

Comparing the current P/E of 15.15x with the Fair Ratio of 31.37x, Grifols screens as undervalued on this metric.

Result: UNDERVALUEDBME:GRF P/E Ratio as at Apr 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 96 top founder-led companies.

Upgrade Your Decision Making: Choose your Grifols Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and on Simply Wall St that means using Narratives, which let you attach a clear story about Grifols to your own forecast for future revenue, earnings and margins, then translate that into a Fair Value you can compare with the current share price.

A Narrative is your view on what is driving Grifols as a business, linked directly to numbers such as expected earnings in 2028, profit margins and the P/E you think is reasonable, so you are not just looking at ratios in isolation but at a joined up story plus model.

On the Community page, investors can choose or create Narratives that range from more optimistic, such as a Fair Value around €21.72 or €21.72 to €23.00, through to more cautious views closer to €9.00, and see instantly how each story translates into a Fair Value compared with today’s price.

As new information arrives, for example updated earnings estimates that move a Fair Value for Grifols from about €15.20 to €15.08, the Narrative refreshes automatically so you can quickly reassess whether your story about the company and its valuation still holds up.

Do you think there's more to the story for Grifols? Head over to our Community to see what others are saying!BME:GRF 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GRF.MC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Company Logo

The global Kawasaki disease market is set for steady growth, propelled by rising disease incidence, better clinical recognition, and advancements in pediatric care. Kawasaki disease, an acute vasculitis mostly affecting children under five, is increasingly recognized among healthcare professionals, boosting early diagnosis and treatment trends in the U.S., Japan, and Europe. Key growth drivers include advancements in diagnostic imaging, use of treatments like IVIG, and the emergence of biologic agents. Technological innovation and government initiatives enhance pediatric care, though challenges like underdiagnosis and high costs persist. Industry leaders, including Takeda and CSL Behring, are investing in research and partnerships.

Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Kawasaki Disease Market - A Global and Regional Analysis: Focus on Treatment Type and Region, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

The global kawasaki disease market is poised for steady expansion over the forecast period, driven by increasing disease incidence, improved clinical recognition, and advancements in pediatric care infrastructure. Kawasaki disease, an acute vasculitis predominantly affecting children under five years, continues to be a critical area of pediatric cardiovascular research. Growing awareness among healthcare professionals and parents regarding early detection and treatment has substantially strengthened the kawasaki disease market across the U.S., Japan, and major European economies.

The kawasaki disease market is witnessing growth propelled by multiple factors, including rising focus on early diagnosis, advancements in diagnostic imaging technologies, and increasing use of established treatment modalities such as intravenous immunoglobulin (IVIG), aspirin, and corticosteroids. The development of biologics and immunomodulatory agents for refractory cases is reshaping the treatment landscape, enhancing patient outcomes, and broadening therapeutic accessibility within the kawasaki disease market.

Continuous technological evolution and government initiatives to strengthen pediatric healthcare have significantly contributed to the kawasaki disease market's expansion. Early detection supported by advanced echocardiography, biomarker discovery, and AI-enabled diagnostic systems is improving accuracy in clinical decision-making. These innovations are expected to further streamline treatment and minimize coronary artery complications among affected children, reinforcing the importance of timely intervention within the kawasaki disease market.

However, the kawasaki disease market faces several challenges, including underdiagnosis in emerging economies, high treatment costs, and limited access to specialized pediatric cardiology facilities. Furthermore, the lack of uniform global clinical guidelines hinders effective disease management. Nevertheless, ongoing research collaborations, expanding clinical trial activity, and strategic government programs aimed at pediatric disease surveillance are expected to address these gaps and promote sustained growth in the kawasaki disease market.

The competitive environment of the kawasaki disease market is defined by pharmaceutical and biotechnology companies investing in innovative immunotherapies and improved IVIG formulations. Major industry players such as Takeda Pharmaceutical Company Limited, CSL Behring, Grifols S.A., ADMA Biologics, Inc., and Octapharma AG are actively involved in expanding their product portfolios through research, partnerships, and global distribution initiatives to strengthen their foothold in the kawasaki disease market.

Story Continues

The kawasaki disease market is expected to evolve through growing research collaborations, enhanced diagnostic precision, and improved global access to treatment, underscoring the importance of early diagnosis and comprehensive disease management.

Looking forward, the global kawasaki disease market is anticipated to maintain strong momentum through 2035, supported by technological advancements, improved reimbursement frameworks, and rising healthcare expenditure on pediatric conditions. Integration of telemedicine, AI-based patient monitoring, and data-driven treatment algorithms will continue to redefine clinical practices and sustain market expansion across both developed and developing economies.

Key Topics Covered:

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Kawasaki Disease Market: Industry Analysis 1.1 Market Overview and Ecosystem 1.2 Epidemiological Analysis 1.3 Key Market Trends 1.3.1 Impact Analysis 1.4 Patent Analysis 1.4.1 Patent Filing Trend (by Country) 1.4.2 Patent Filing Trend (by Year) 1.5 Regulatory Landscape 1.6 Ongoing Clinical Trials 1.7 Market Dynamics 1.7.1 Overview 1.7.2 Market Drivers 1.7.3 Market Restraints 1.7.4 Market Opportunities

2. Global Kawasaki Disease Market, by Treatment Type, $Million, 2024-2035 2.1 Intravenous Immunoglobulin (IVIG) 2.2 Anti-inflammatory Drugs 2.3 Corticosteroids 2.4 Others

3. Global Kawasaki Disease Market, by Region, $Million, 2024-2035 3.1 North America 3.1.1 Market Dynamics 3.1.2 Market Sizing and Forecast 3.1.3 North America Kawasaki Disease Market, by Country 3.1.3.1 U.S. 3.2 Europe 3.2.1 Market Dynamics 3.2.2 Market Sizing and Forecast 3.2.3 Europe Kawasaki Disease Market, by Country 3.2.3.1 U.K. 3.2.3.2 France 3.2.3.3 Germany 3.2.3.4 Italy 3.2.3.5 Spain 3.3 Asia-Pacific 3.3.1 Market Dynamics 3.3.2 Market Sizing and Forecast 3.3.3 Asia-Pacific Kawasaki Disease Market, by Country 3.3.3.1 Japan 3.3.3.2 China 3.3.3.3 South Korea 3.3.3.4 Australia 3.3.3.5 India 3.4 Rest-of-the-World 3.4.1 Market Dynamics 3.4.2 Market Sizing and Forecast

4. Global Kawasaki Disease Market, Competitive Landscape and Company Profiles 4.1 Competitive Landscape 4.1.1 Mergers and Acquisitions 4.1.2 Partnership, Alliances and Business Expansion 4.1.3 New Offerings 4.1.4 Regulatory Activities 4.1.5 Funding Activities 4.2 Company Profiles 4.2.1 Grifols 4.2.1.1 Overview 4.2.1.2 Top Products / Product Portfolio 4.2.1.3 Top Competitors 4.2.1.4 Target Customers/End-Users 4.2.1.5 Key Personnel 4.2.1.6 Analyst View 4.2.2 ADMA Biologics, Inc. 4.2.3 CSL Behring LLC. 4.2.4 Takeda Pharmaceutical Company Limited 4.2.5 Octapharma AG 4.2.6 BioCare, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/o7ndcy

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Grifols (NASDAQ:GRFS) is one of the

10 Overlooked Growth Stocks to Buy Now.

Grifols (NASDAQ:GRFS) is one of the overlooked growth stocks to buy now. On March 17, Grifols unveiled proof-of-concept data from its Chronos-PD program, showing that molecular changes associated with Parkinson’s disease/PD can be detected up to 12 years before a clinical diagnosis. The study analyzed over 2,600 longitudinal plasma samples using AI and advanced proteomics. This deep profiling allowed researchers to track the evolution of distinct proteins over time, potentially establishing an early-warning system for a disease that currently lacks early detection biomarkers.

The research identified reproducible early molecular signals, including the discovery of a major modulation in the CXCL12-cell adhesion molecules-integrin axis. This signaling network is responsible for governing leukocyte trafficking and blood-brain barrier integrity, both of which are central to the neuroinflammation seen in PD. By uncovering these distinct molecular patterns, Grifols (NASDAQ:GRFS) aims to support future efforts in patient stratification and precision medicine, providing a window for intervention before significant dopamine-producing brain cells are lost.Grifols (GRFS) Unveils AI-Driven Data for Early Parkinson’s Disease Detection

Pixabay/Public Domain

Chronos-PD is part of a broader Grifols initiative that uses a proprietary library of over 100 million plasma samples connected to real-world data. The study validated early biomarkers across five independent cohorts. Dr. Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer, noted that the platform’s ability to search for the earliest signs of disease could accelerate the development of new diagnostics and disease-modifying therapeutics for various public health challenges beyond Parkinson’s.

Grifols (NASDAQ:GRFS) is a healthcare company that deals in plasma-derived medicines through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company provides plasma-derived therapeutics, diagnostic systems, hospital healthcare solutions, and integrated pharmaceutical services.

While we acknowledge the potential of GRFS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Grifols, S.A. is one of the best healthcare stocks on this list.

TheFly reported on April 2 that CBC News reported that Health Canada introduced new regulatory conditions on GRFS’ paid plasma collection centers nationwide after repeated inspection failures revealed ongoing operational issues. These included gaps in donor screening, inadequate staff training, and non-compliance with standard procedures. The measures will remain until the company demonstrates consistent adherence to regulatory requirements.

Separately, on April 13, Grifols, S.A. (NASDAQ:GRFS) announced plans to repurchase €500 million of its 7.5% senior secured notes maturing in 2030 as part of efforts to lower borrowing costs and reinforce its financial position. The move targets the reduction of its most expensive debt and aligns with broader refinancing initiatives. The company recently completed a strong loan syndication, including an expanded Term Loan B of about €3 billion and a $2 billion revolving credit facility, supported by institutional investors.Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers

Following the expected completion of this refinancing, GRFS will not face significant debt maturities until late 2028. These actions are designed to decrease overall debt levels, reduce interest expenses, and improve the company’s debt timeline while preserving liquidity. The planned note redemption is contingent upon the closing of the new financing arrangements and the successful restructuring of debt obligations due in 2027.

Grifols, S.A. (NASDAQ:GRFS) is a global healthcare company specializing in plasma-derived therapies and transfusion medicine. It develops and manufactures biologics to treat chronic and rare diseases, operating an extensive plasma collection network and advanced production facilities worldwide.

While we acknowledge the potential of GRFS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

Wondering whether Grifols at €9.27 is offering value right now, or if the recent price is already baking in most of the good news? The stock has had a mixed run, with a 3.5% gain over the last 7 days, an 11.9% decline over 30 days, a 17.2% decline year to date, but an 11.6% return over the past year. These swings sit against a longer track record of a 3.6% return over 3 years and a 57.6% decline over 5 years, which can influence how you think about risk and patience. Together, these figures frame the question of whether the current price reflects temporary sentiment or something more structural. Grifols currently holds a valuation score of 5 out of 6, which suggests several checks point to the shares looking undervalued. The next step is to compare the standard valuation methods, before finishing with a more complete way to think about what the stock might be worth.

Find out why Grifols's 11.6% return over the last year is lagging behind its peers.

Approach 1: Grifols Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes the cash Grifols is expected to generate in the future, then discounts those amounts back into today’s money to estimate what the whole business could be worth per share.

Grifols last twelve months free cash flow stands at about €657.2 million. Analysts have specific estimates for the next few years, and beyond that the cash flows are extrapolated using the same 2 Stage Free Cash Flow to Equity approach. On this basis, free cash flow for 2030 is projected at €1,618.0 million, with a full set of annual projections between 2026 and 2035 discounted back to present values.

Putting all of those discounted cash flows together gives an estimated intrinsic value of about €25.21 per share. Against the current share price of €9.27, this implies an intrinsic discount of roughly 63.2%, which points to Grifols trading well below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Grifols is undervalued by 63.2%. Track this in your watchlist or portfolio, or discover 250 more high quality undervalued stocks.GRF Discounted Cash Flow as at Apr 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Grifols.

Approach 2: Grifols Price vs Earnings

For a profitable company like Grifols, the P/E ratio is a useful way to think about what you are paying for each euro of current earnings. It lets you compare the share price with how much profit the business is already generating, rather than focusing only on future estimates.

Story Continues

In broad terms, higher growth expectations and lower perceived risk tend to support a higher “normal” P/E ratio, while slower growth or higher risk usually justify a lower one. Grifols currently trades on a P/E of 15.7x. That sits below the Biotechs industry average of 25.1x and the peer group average of 31.7x, which suggests the market is applying a lower multiple than many comparable companies.

Simply Wall St’s Fair Ratio for Grifols is 31.5x. This is a proprietary estimate of what the P/E might be given its earnings growth profile, profit margins, industry, market cap and risk factors. Because it incorporates these company specific inputs, the Fair Ratio can give a more tailored reference point than a simple comparison to peers or an industry average. Set against the current 15.7x P/E, the 31.5x Fair Ratio indicates the shares are trading below this fair multiple estimate.

Result: UNDERVALUEDBME:GRF P/E Ratio as at Apr 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 96 top founder-led companies.

Upgrade Your Decision Making: Choose your Grifols Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and on Simply Wall St this takes the form of Narratives, which let you connect your view of Grifols’ future with numbers like revenue, earnings, margins and a Fair Value that you can compare directly to today’s price.

A Narrative is your story about the company written in financial terms. Instead of just accepting a single DCF or P/E output, you choose assumptions for things like how fast sales might grow, what margins could look like, and what P/E you think is reasonable, and the platform turns that into a Fair Value estimate.

Because Narratives live inside the Community page and are used by millions of investors on Simply Wall St, you can quickly see how your view lines up with others and use the gap between Fair Value and the current market price to help decide if the stock sits on your watchlist, looks closer to a buy, or feels more like a candidate to reduce.

These Narratives also refresh when new information such as earnings releases, analyst target changes like the €23.0 high case or the €9.0 low case, or updated revenue and margin assumptions are added, so your Grifols view can stay current instead of being a one off spreadsheet exercise.

For Grifols however we'll make it really easy for you with previews of two leading Grifols Narratives:

🐂 Grifols Bull Case

Fair value in this bullish narrative: €15.08

Implied discount to this fair value vs the €9.27 share price: around 38.6%.

Revenue growth assumption: about 5.6% a year.

Analysts in this camp expect steady revenue growth supported by plasma therapies, new product launches and wider market reach. They factor in improving margins, gradual deleveraging and stronger free cash flow as operations and the balance sheet normalise. Their consensus price target of €16.48 sits above both the current share price and this fair value estimate, but still depends on earnings reaching about €893.1m by 2028 and a future P/E of 17.2x.

🐻 Grifols Bear Case

Fair value in this bearish narrative: €9.00

Implied premium to this fair value vs the €9.27 share price: about 3.0% overvalued.

Revenue growth assumption: about 5.3% a year.

The bearish view places more weight on future competition from gene therapies and synthetic biologics that could limit long term demand for plasma products. It also reflects pressure from regulation, donor availability and higher operating and compliance costs that could constrain margins. Under this narrative, a €9.00 fair value lines up with the lowest analyst target, with 2028 earnings assumed at about €782.4m on a 10.5x P/E multiple and a 10.2% discount rate.

Both narratives rely on different views about how quickly revenue grows, how far margins improve and what P/E multiple is realistic a few years from now. Using them side by side can help you decide which set of assumptions feels closer to your own expectations before you commit to any position size or holding period.

Do you think there's more to the story for Grifols? Head over to our Community to see what others are saying!BME:GRF 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GRF.MC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments